Needle-free monitoring and drug delivery
Management | Board of Directors
CEO, President and Chairman of the Board
Dr. Mooney joined Echo in September 2007 as a result of the merger of Sontra Medical Corporation and then privately-held Echo Therapeutics, Inc. (ETI), for which he served as President, Chief Executive Officer and director from September 2006 through the date of the merger. Prior to joining ETI, Dr. Mooney was President, Chief Executive Officer and Chairman of Aphton Corporation (Nasdaq: APHT), where he had also served as Chief Medical Officer. Prior to that, Dr. Mooney served as Senior Biotechnology Analyst at Thomas Weisel Partners, LLC, a full service merchant banking firm and as Senior Biotechnology Analyst at Janney Montgomery Scott, LLC, a full services investment banking firm. Dr. Mooney received his medical degree from the Jefferson Medical College of Thomas Jefferson University and trained in surgery at Thomas Jefferson University Hospital.
Chief Financial Officer
Mr. Schnittker brings a broad base of financial experience to Echo Therapeutics. Most recently, he served as Vice President – Administration, Corporate Secretary and Chief Accounting Officer of Soligenix, Inc., a publicly-traded biotechnology company. Prior to that, Mr. Schnittker served as the Senior Vice President and CFO for VioQuest Pharmaceuticals Inc., Micromet Inc., CytogenCorporation, and Genaera Corporation, all publicly-traded biotechnology companies. Mr. Schnittker has also held prior financial management positions at GSI Commerce, Rhône-Poulenc Rorer (now part of Sanofi-Aventis), and PricewaterhouseCoopers. He received his B.A. degree in economics and business from Lafayette College and is a certified public accountant licensed in theState of New Jersey.
General Counsel
Ms. Burke joined Echo Therapeutics in 2008 after serving as General Counsel of privately-held Echo Therapeutics, Inc., which merged with Sontra Medical Corporation to form Echo Therapeutics in September 2007. Prior to Echo, Ms. Burke was Director of Legal Affairs at Cato Research Ltd., a global contract research and development organization, and an Associate with Cato BioVentures. Ms. Burke has also held prior legal positions at Devine, Millimet and Branch, a New England law firm, Investors Title Company (NASDAQ: ITIC), a holding company engaged in title insurance and investment management services, and Hemodynamic Therapeutics, a pharmaceutical company. Ms. Burke received her B.A. from Mount Holyoke College and her J.D. from the College of William and Mary, Marshall-Wythe School of Law.
Senior Vice President, Research & Development
Mr. Gary brings more than 25 years of experience to Echo Therapeutics in the point-of-care and diabetes markets. Prior to joining Echo, he served as R&D Venture Director for Abbott Diabetes Care where he led the design, development and launch of numerous hospital-based point-of-care and consumer diabetes testing systems. Mr. Gary served as General Manager of Breathquant Medical where he led the design and successful clinical trials for Breathquant's novel low-cost diagnostic system for the rapid detection of pulmonary embolism. Mr. Gary holds a B.S. in Bioengineering and an M.S. in Chemical Engineering from Columbia University and an MBA from Boston University.
Senior Vice President, Operations
Mr. Deweese joined Echo Therapeutics following 16 years of experience with Abbott Laboratories (formerly MediSense). As the Director of R & D, Program Management, and OEM Operations at Abbot Laboratories, Mr. Deweese led the technical product development, program management, and high volume manufacturing of portable glucose meters for hospital and home use. Prior to joining MediSense, Mr. Deweese was a co-founder and Vice President of Massachusetts Technology Associates (Mass Tech), a company that provided engineering and manufacturing services to its client base, specializing in high quality, rapid turnaroundprototype and assembly services. Mr. Deweese studied engineering at Massachusetts Institute of Technology.
CEO, President and Chairman of the Board
Mr. Enright joined our Board of Directors in March 2008. He has more than 30 years of financial experience with public companies, including as Senior Vice President and Chief Financial Officer of KeySpan Corporation, a NYSE public utility company. Mr. Enright currently serves as a director and Audit Committee Chairman of certain of the funds managed by Gabelli Funds, LLC, a leading mutual fund manager, positions he has held since 1991. Mr. Enright holds a B.S. degree in Accounting from Fordham.
Mr. Grieco joined our Board of Directors in February 2011. He brings approximately 30 years of healthcare industry experience. Since 2008, Mr. Grieco has served as the Managing Director of Arcadia Strategies, LLC, a business and legal consulting organization servicing healthcare, science and technology companies. From 2003 to 2008 he served as Senior Vice President and General Counsel of American Science and Engineering, Inc., an x-ray inspection technology company, and prior to that he served as Senior Vice President and General Counsel of IDX Systems Corporation, a healthcare information technology company. From 1995 to 1999, he was Senior Vice President and General Counsel for Fresenius Medical Care North America. Mr. Grieco received a B.S. from Boston College, an M.S. in Health Policy and Management from Harvard University and a J.D. from Boston College Law School.
Mr. Smith joined our Board of Directors in February 2011. He brings over 30 years of financial management experience including his position as Vice President and Chief Financial Officer of Orchid Cellmark, Inc., a leading international provider of DNA testing services, where he led all aspects of finance, including control, financial reporting, tax, treasury, and M&A. His experience also includes over 20 years, with Wyeth and American Cyanamid Company, most recently as Vice President of Finance. During his time at Wyeth and Cyanamid, he obtained extensive commercial international business experience and was involved in numerous new product commercialization projects. Mr. Smith started his accounting career at PricewaterhouseCoopers. He is licensed as a certified public accountant.
